1 Report Prologue
2 Executive Summary
3 Market Introduction
3.1 Definition 20
3.2 Scope of the Study 20
3.3 Assumptions & Limitations 20
3.3.1 Assumptions 20
3.3.2 Limitations 20
3.4 Market Structure 21
4 Research Methodology
4.1 Research Process 23
4.2 Primary Research 24
4.3 Secondary Research 25
4.4 Market Size Estimation 26
4.5 Forecast Model 26
5 Market Dynamics
5.1 Introduction 28
5.2 Drivers 29
5.2.1 Rising prevalence of epilepsy amongst the geriatric population 29
5.2.2 Increasing cases of brain injuries due to road accidents 29
5.2.3 Rising neurological disorders 29
5.2.4 Increasing research funding in epilepsy 29
5.3 Restraints 30
5.3.1 Loss of patent protection for branded drugs 30
5.3.2 High costs associated with the treatment of epilepsy 30
5.4 Opportunities 30
5.4.1 Entering developing economies 30
6 Market Factor Analysis
6.1 Porter’s Five Forces Analysis 32
6.1.1 Bargaining Power of Suppliers 32
6.1.2 Bargaining Power of Buyers 33
6.1.3 Threat of New Entrants 33
6.1.4 Threat of Substitutes 33
6.1.5 Intensity of Rivalry 33
6.2 Supply Chain Analysis 34
6.2.1 R&D 34
6.2.2 Manufacturing 34
6.2.3 Distribution 34
6.2.4 Marketing & Sales 34
6.2.5 Post-Sales Monitoring 35
6.3 Investment Opportunities 35
6.4 Pricing Analysis 35
6.5 Demographic Analysis 36
7 Epilepsy Market, by Condition
7.1 Overview 39
7.1.1 Epilepsy Drug-Resistant/ Intractable Epilepsy 41
7.1.2 Others 41
8 Epilepsy Market, by Diagnosis & Treatment
8.1 Overview 43
8.1.1 Diagnosis & Treatment 45
9 Epilepsy Market, by End User
9.1 Overview 50
10 Global Epilepsy Market, by Region
10.1 Overview 56
10.2 Americas 59
Epilepsy Market, by Condition
Epilepsy Market, by Diagnosis & Treatment
Epilepsy Market, by End User
10.2.1 North America 64
Epilepsy Market, by Condition
Epilepsy Market, by Diagnosis & Treatment
Epilepsy Market, by End User
10.2.1.1 US 68
Epilepsy Market, by Condition
Epilepsy Market, by Diagnosis & Treatment
Epilepsy Market, by End User
10.2.1.2 CANADA 72
Epilepsy Market, by Condition
Epilepsy Market, by Diagnosis & Treatment
Epilepsy Market, by End User
10.2.2 Latin America 75
Epilepsy Market, by Condition
Epilepsy Market, by Diagnosis & Treatment
Epilepsy Market, by End User
10.2.2.1 BRAZIL 79
Epilepsy Market, by Condition
Epilepsy Market, by Diagnosis & Treatment
Epilepsy Market, by End User
10.2.2.2 REST OF LATIN AMERICA 83
Epilepsy Market, by Condition
Epilepsy Market, by Diagnosis & Treatment
Epilepsy Market, by End User
10.3 Europe 87
Epilepsy Market, by Condition
Epilepsy Market, by Diagnosis & Treatment
Epilepsy Market, by End User
10.3.1 Western Europe 92
Epilepsy Market, by Condition
Epilepsy Market, by Diagnosis & Treatment
Epilepsy Market, by End User
10.3.1.1 Germany 96
Epilepsy Market, by Condition
Epilepsy Market, by Diagnosis & Treatment
Epilepsy Market, by End User
10.3.1.2 France 100
Epilepsy Market, by Condition
Epilepsy Market, by Diagnosis & Treatment
Epilepsy Market, by End User
10.3.1.3 UK 103
Epilepsy Market, by Condition
Epilepsy Market, by Diagnosis & Treatment
Epilepsy Market, by End User
10.3.2 Italy 107
Epilepsy Market, by Condition
Epilepsy Market, by Diagnosis & Treatment
Epilepsy Market, by End User
10.3.3 Spain 110
Epilepsy Market, by Condition
Epilepsy Market, by Diagnosis & Treatment
Epilepsy Market, by End User
10.3.4 Rest of Western Europe 114
Epilepsy Market, by Condition
Epilepsy Market, by Diagnosis & Treatment
Epilepsy Market, by End User
10.3.5 Eastern Europe 117
Epilepsy Market, by Condition
Epilepsy Market, by Diagnosis & Treatment
Epilepsy Market, by End User
10.4 Asia-Pacific 121
Epilepsy Market, by Condition
Epilepsy Market, by Diagnosis & Treatment
Epilepsy Market, by End User
10.4.1.1 Japan 126
Epilepsy Market, by Condition
Epilepsy Market, by Diagnosis & Treatment
Epilepsy Market, by End User
10.4.1.2 China 130
Epilepsy Market, by Condition
Epilepsy Market, by Diagnosis & Treatment
Epilepsy Market, by End User
10.4.2 India 134
Epilepsy Market, by Condition
Epilepsy Market, by Diagnosis & Treatment
Epilepsy Market, by End User
10.4.3 Australia 137
Epilepsy Market, by Condition
Epilepsy Market, by Diagnosis & Treatment
Epilepsy Market, by End User
10.4.4 South Korea 141
Epilepsy Market, by Condition
Epilepsy Market, by Diagnosis & Treatment
Epilepsy Market, by End User
10.4.5 Rest of Asia-Pacific 144
Epilepsy Market, by Condition
Epilepsy Market, by Diagnosis & Treatment
Epilepsy Market, by End User
10.5 Middle East & Africa 148
Epilepsy Market, by Condition
Epilepsy Market, by Diagnosis & Treatment
Epilepsy Market, by End User
10.6 Middle East 153
Epilepsy Market, by Condition
Epilepsy Market, by Diagnosis & Treatment
Epilepsy Market, by End User
10.6.1.1 Saudi Arabia 157
Epilepsy Market, by Condition
Epilepsy Market, by Diagnosis & Treatment
Epilepsy Market, by End User
10.6.1.2 Rest of Middle East 160
Epilepsy Market, by Condition
Epilepsy Market, by Diagnosis & Treatment
Epilepsy Market, by End User
10.6.2 Africa 164
Epilepsy Market, by Condition
Epilepsy Market, by Diagnosis & Treatment
Epilepsy Market, by End User
11 Competitive Landscape
11.1 Company Market Share Analysis 169
11.1.1 Introduction 169
12 Company Profile
12.1 LivaNova PLC 172
12.1.1 Company Overview 172
12.1.2 Financial Overview 172
12.1.3 Products/Services Offered 173
12.1.4 Key Development 173
12.1.5 SWOT Analysis 173
12.1.6 Key Strategies 173
12.2 GlaxoSmithKline PLC 174
12.2.1 Company Overview 174
12.2.2 Financial Overview 174
12.2.3 Products/Services Offered 174
12.2.4 Key Development 175
12.2.5 SWOT Analysis 175
12.2.6 Key Strategies 175
12.3 Eisai Co. Ltd 176
12.3.1 Company Overview 176
12.3.2 Financial Overview 176
12.3.3 Products/Services Offered 176
12.3.4 Key Development 177
12.3.5 SWOT Analysis 177
12.3.6 Key Strategies 177
12.4 Pfizer Inc 178
12.4.1 Company Overview 178
12.4.2 Financial Overview 178
12.4.3 Products/Services Offered 178
12.4.4 Key Developments 179
12.4.5 SWOT Analysis 179
12.4.6 Key Strategies 179
12.5 Medtronic PLC 180
12.5.1 Company Overview 180
12.5.2 Financial Overview 180
12.5.3 Products/Services Offered 181
12.5.4 Key Developments 181
12.5.5 SWOT Analysis 181
12.5.6 Key Strategies 181
12.6 UCB SA 182
12.6.1 Company Overview 182
12.6.2 Financial Overview 182
12.6.3 Products/Services Offered 183
12.6.4 Key Developments 183
12.6.5 SWOT Analysis 183
12.6.6 Key Strategies 183
12.7 NeuroPace Inc 184
12.7.1 Company Overview 184
12.7.2 Financial Overview 184
12.7.3 Products/Services Offered 184
12.7.4 Key Developments 184
12.7.5 SWOT Analysis 184
12.7.6 Key Strategies 184
12.8 GW Pharmaceuticals PLC 185
12.8.1 Company Overview 185
12.8.2 Financial Overview 185
12.8.3 Products/Services Offered 185
12.8.4 Key Developments 186
12.8.5 SWOT Analysis 186
12.8.6 Key Strategies 186
12.9 Novartis AG 187
12.9.1 Company Overview 187
12.9.2 Financial Overview 187
12.9.3 Products/Services Offered 187
12.9.4 Key Developments 188
12.9.5 SWOT Analysis 188
12.9.6 Key Strategies 188
12.10 Johnson & Johnson Services Inc. 189
12.10.1 Company Overview 189
12.10.2 Financial Overview 189
12.10.3 Products/Services Offered 189
12.10.4 Key Developments 190
12.10.5 SWOT Analysis 190
12.10.6 Key Strategies 190
12.11 Abbott Laboratories 191
12.11.1 Company Overview 191
12.11.2 Financial Overview 191
12.11.3 Products/Services Offered 191
12.11.4 Key Developments 192
12.11.5 SWOT Analysis 192
12.11.6 Key Strategies 192
13 Appendix
13.1 Discussion Blue Print 194
14 List of Tables
TABLE 1 MARKET SYNOPSIS 18
TABLE 2 PRIMARY INTERVIEWS 23
TABLE 3 GLOBAL EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 40
TABLE 4 GLOBAL EPILEPSY MARKET, FOR EPILEPSY DRUG-RESISTANT/ INTRACTABLE EPILEPSY, BY REGION 2020–2027 (USD MILLION) 41
TABLE 5 GLOBAL EPILEPSY MARKET, FOR OTHERS, BY REGION 2020–2027 (USD MILLION) 41
TABLE 6 GLOBAL EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 45
TABLE 7 GLOBAL EPILEPSY MARKET, FOR DIAGNOSIS, BY REGION, 2020-2027 (USD MILLION) 46
TABLE 8 GLOBAL EPILEPSY MARKET, FOR TREATMENT, BY REGION, 2020-2027 (USD MILLION) 46
TABLE 9 GLOBAL EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 47
TABLE 10 GLOBAL EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 47
TABLE 11 GLOBAL EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 48
TABLE 12 GLOBAL EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 48
TABLE 13 GLOBAL EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 51
TABLE 14 GLOBAL EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 52
TABLE 15 GLOBAL EPILEPSY MARKET, FOR HOSPITALS, BY REGION 2020–2027 (USD MILLION) 52
TABLE 16 GLOBAL EPILEPSY MARKET, FOR CLINICS (FAMILY PRACTITIONERS/ INTERNAL MEDICINE), BY REGION 2020–2027 (USD MILLION) 53
TABLE 17 GLOBAL EPILEPSY MARKET, FOR AMBULATORY SURGICAL CENTERS (OUTPATIENT CENTERS), BY REGION 2020–2027 (USD MILLION) 53
TABLE 18 GLOBAL EPILEPSY MARKET, FOR DIAGNOSTIC CENTERS, BY REGION 2020–2027 (USD MILLION) 54
TABLE 19 GLOBAL EPILEPSY MARKET, BY REGION, 2020–2027 (USD MILLION) 57
TABLE 20 GLOBAL PREVALENCE OF EPILEPSY 2020-2027 57
TABLE 21 GLOBAL INCIDENCE OF EPILEPSY 2020-2027 57
TABLE 22 AMERICAS: EPILEPSY MARKET, BY REGION, 2020–2027 (USD MILLION) 60
TABLE 23 AMERICAS: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 60
TABLE 24 AMERICAS: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 60
TABLE 25 AMERICAS: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 61
TABLE 26 AMERICAS: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 61
TABLE 27 AMERICAS: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 62
TABLE 28 AMERICAS: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 62
TABLE 29 AMERICAS: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 63
TABLE 30 AMERICAS: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 63
TABLE 31 NORTH AMERICA: EPILEPSY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 64
TABLE 32 NORTH AMERICA: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 64
TABLE 33 NORTH AMERICA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 65
TABLE 34 NORTH AMERICA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 65
TABLE 35 NORTH AMERICA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 66
TABLE 36 NORTH AMERICA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 66
TABLE 37 NORTH AMERICA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 67
TABLE 38 NORTH AMERICA: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 67
TABLE 39 NORTH AMERICA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 68
TABLE 40 US: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 68
TABLE 41 US: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 69
TABLE 42 US: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 69
TABLE 43 US: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 70
TABLE 44 US: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 70
TABLE 45 US: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 71
TABLE 46 US: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 71
TABLE 47 CANADA: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 72
TABLE 48 CANADA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 72
TABLE 49 CANADA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 72
TABLE 50 CANADA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 73
TABLE 51 CANADA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 73
TABLE 52 CANADA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 74
TABLE 53 CANADA: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 74
TABLE 54 CANADA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 75
TABLE 55 LATIN AMERICA: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 75
TABLE 56 LATIN AMERICA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 76
TABLE 57 LATIN AMERICA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 76
TABLE 58 LATIN AMERICA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 77
TABLE 59 LATIN AMERICA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 78
TABLE 60 LATIN AMERICA: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 78
TABLE 61 LATIN AMERICA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 79
TABLE 62 BRAZIL: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 79
TABLE 63 BRAZIL: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 79
TABLE 64 BRAZIL: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 80
TABLE 65 BRAZIL: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 80
TABLE 66 BRAZIL: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 81
TABLE 67 BRAZIL: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 81
TABLE 68 BRAZIL: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 82
TABLE 69 REST OF LATIN AMERICA: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 83
TABLE 70 REST OF LATIN AMERICA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 83
TABLE 71 REST OF LATIN AMERICA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 83
TABLE 72 REST OF LATIN AMERICA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 84
TABLE 73 REST OF LATIN AMERICA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 84
TABLE 74 REST OF LATIN AMERICA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 85
TABLE 75 REST OF LATIN AMERICA: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 85
TABLE 76 REST OF LATIN AMERICA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 86
TABLE 77 EUROPE: EPILEPSY MARKET, BY REGION, 2020–2027 (USD MILLION) 88
TABLE 78 EUROPE: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 88
TABLE 79 EUROPE: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 88
TABLE 80 EUROPE: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 89
TABLE 81 EUROPE: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 89
TABLE 82 EUROPE: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 90
TABLE 83 EUROPE: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 90
TABLE 84 EUROPE: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 91
TABLE 85 EUROPE: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 91
TABLE 86 WESTERN EUROPE: EPILEPSY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 92
TABLE 87 WESTERN EUROPE: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 93
TABLE 88 WESTERN EUROPE: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 93
TABLE 89 WESTERN EUROPE: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 93
TABLE 90 WESTERN EUROPE: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 94
TABLE 91 WESTERN EUROPE: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 94
TABLE 92 WESTERN EUROPE: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 95
TABLE 93 WESTERN EUROPE: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 95
TABLE 94 WESTERN EUROPE: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 96
TABLE 95 GERMANY: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 96
TABLE 96 GERMANY: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 97
TABLE 97 GERMANY: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 97
TABLE 98 GERMANY: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 98
TABLE 99 GERMANY: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 98
TABLE 100 GERMANY: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 99
TABLE 101 GERMANY: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 99
TABLE 102 FRANCE: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 100
TABLE 103 FRANCE: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 100
TABLE 104 FRANCE: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 100
TABLE 105 FRANCE: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 101
TABLE 106 FRANCE: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 101
TABLE 107 FRANCE: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 102
TABLE 108 FRANCE: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 102
TABLE 109 FRANCE: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 103
TABLE 110 UK: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 103
TABLE 111 UK: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 103
TABLE 112 UK: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 104
TABLE 113 UK: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 104
TABLE 114 UK: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 105
TABLE 115 UK: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 105
TABLE 116 UK: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 106
TABLE 117 UK: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 106
TABLE 118 ITALY: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 107
TABLE 119 ITALY: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 107
TABLE 120 ITALY: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 107
TABLE 121 ITALY: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 108
TABLE 122 ITALY: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 108
TABLE 123 ITALY: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 109
TABLE 124 ITALY: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 109
TABLE 125 ITALY: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 110
TABLE 126 SPAIN: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 110
TABLE 127 SPAIN: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 110
TABLE 128 SPAIN: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 111
TABLE 129 SPAIN: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 111
TABLE 130 SPAIN: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 112
TABLE 131 SPAIN: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 112
TABLE 132 SPAIN: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 113
TABLE 133 SPAIN: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 113
TABLE 134 REST OF WESTERN EUROPE: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 114
TABLE 135 REST OF WESTERN EUROPE: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 114
TABLE 136 REST OF WESTERN EUROPE: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 115
TABLE 137 REST OF WESTERN EUROPE: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 115
TABLE 138 REST OF WESTERN EUROPE: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 116
TABLE 139 REST OF WESTERN EUROPE: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 116
TABLE 140 REST OF WESTERN EUROPE: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 117
TABLE 141 EASTERN EUROPE: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 117
TABLE 142 EASTERN EUROPE: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 117
TABLE 143 EASTERN EUROPE: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 118
TABLE 144 EASTERN EUROPE: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 118
TABLE 145 EASTERN EUROPE: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 119
TABLE 146 EASTERN EUROPE: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 119
TABLE 147 EASTERN EUROPE: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 120
TABLE 148 EASTERN EUROPE: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 120
TABLE 149 ASIA-PACIFIC: ORPHAN DRUGS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 122
TABLE 150 ASIA-PACIFIC: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 122
TABLE 151 ASIA-PACIFIC: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 123
TABLE 152 ASIA-PACIFIC: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 123
TABLE 153 ASIA-PACIFIC: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 124
TABLE 154 ASIA-PACIFIC: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 124
TABLE 155 ASIA-PACIFIC: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 125
TABLE 156 ASIA-PACIFIC: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 125
TABLE 157 ASIA-PACIFIC: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 126
TABLE 158 JAPAN: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 127
TABLE 159 JAPAN: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 127
TABLE 160 JAPAN: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 128
TABLE 161 JAPAN: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 128
TABLE 162 JAPAN: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 129
TABLE 163 JAPAN: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 129
TABLE 164 JAPAN: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 130
TABLE 165 CHINA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 130
TABLE 166 CHINA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 131
TABLE 167 CHINA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 131
TABLE 168 CHINA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 132
TABLE 169 CHINA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 132
TABLE 170 CHINA: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 133
TABLE 171 CHINA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 133
TABLE 172 INDIA: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 134
TABLE 173 INDIA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 134
TABLE 174 INDIA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 134
TABLE 175 INDIA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 135
TABLE 176 INDIA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 135
TABLE 177 INDIA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 136
TABLE 178 INDIA: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 136
TABLE 179 INDIA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 137
TABLE 180 AUSTRALIA: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 137
TABLE 181 AUSTRALIA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 137
TABLE 182 AUSTRALIA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 138
TABLE 183 AUSTRALIA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 138
TABLE 184 AUSTRALIA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 139
TABLE 185 AUSTRALIA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 139
TABLE 186 AUSTRALIA: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 140
TABLE 187 AUSTRALIA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 140
TABLE 188 SOUTH KOREA: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 141
TABLE 189 SOUTH KOREA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 141
TABLE 190 SOUTH KOREA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 141
TABLE 191 SOUTH KOREA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 142
TABLE 192 SOUTH KOREA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 142
TABLE 193 SOUTH KOREA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 143
TABLE 194 SOUTH KOREA: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 143
TABLE 195 SOUTH KOREA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 144
TABLE 196 REST OF ASIA-PACIFIC: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 144
TABLE 197 REST OF ASIA-PACIFIC: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 144
TABLE 198 REST OF ASIA-PACIFIC: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 145
TABLE 199 REST OF ASIA-PACIFIC: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 145
TABLE 200 REST OF ASIA-PACIFIC: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 146
TABLE 201 REST OF ASIA-PACIFIC: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 146
TABLE 202 REST OF ASIA-PACIFIC: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 147
TABLE 203 REST OF ASIA-PACIFIC: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 147
TABLE 204 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, BY REGION, 2020–2027 (USD MILLION) 149
TABLE 205 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 149
TABLE 206 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 149
TABLE 207 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 150
TABLE 208 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 150
TABLE 209 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 151
TABLE 210 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 151
TABLE 211 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 152
TABLE 212 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 152
TABLE 213 MIDDLE EAST: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 153
TABLE 214 MIDDLE EAST: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 153
TABLE 215 MIDDLE EAST: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 154
TABLE 216 MIDDLE EAST: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 154
TABLE 217 MIDDLE EAST: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 155
TABLE 218 MIDDLE EAST: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 155
TABLE 219 MIDDLE EAST: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 156
TABLE 220 MIDDLE EAST: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 156
TABLE 221 SAUDI ARABIA: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 157
TABLE 222 SAUDI ARABIA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 157
TABLE 223 SAUDI ARABIA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 157
TABLE 224 SAUDI ARABIA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 158
TABLE 225 SAUDI ARABIA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 158
TABLE 226 SAUDI ARABIA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 159
TABLE 227 SAUDI ARABIA: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 159
TABLE 228 SAUDI ARABIA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 160
TABLE 229 REST OF MIDDLE EAST: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 160
TABLE 230 REST OF MIDDLE EAST: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 160
TABLE 231 REST OF MIDDLE EAST: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 161
TABLE 232 REST OF MIDDLE EAST: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 161
TABLE 233 REST OF MIDDLE EAST: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 162
TABLE 234 REST OF MIDDLE EAST: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 162
TABLE 235 REST OF MIDDLE EAST: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 163
TABLE 236 REST OF MIDDLE EAST: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 163
TABLE 237 AFRICA: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 164
TABLE 238 AFRICA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 164
TABLE 239 AFRICA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 164
TABLE 240 AFRICA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 165
TABLE 241 AFRICA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 165
TABLE 242 AFRICA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 166
TABLE 243 AFRICA: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 166
TABLE 244 AFRICA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 167
15 List of Figures
FIGURE 1 GLOBAL EPILEPSY MARKET: MARKET STRUCTURE 21
FIGURE 2 RESEARCH PROCESS 23
FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH 26
FIGURE 4 PORTER’S FIVE FORCES ANALYSIS OF THE GLOBAL EPILEPSY MARKET 32
FIGURE 5 SUPPLY CHAIN: EPILEPSY MARKET 34
FIGURE 6 GLOBAL EPILEPSY MARKET SHARE, BY CONDITION, 2020 (%) 39
FIGURE 7 GLOBAL EPILEPSY MARKET, BY CONDITION, 2020 & 2027 40
FIGURE 8 GLOBAL EPILEPSY MARKET SHARE, BY DIAGNOSIS & TREATMENT, 2020 (%) 44
FIGURE 9 GLOBAL EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020 & 2027 45
FIGURE 10 GLOBAL EPILEPSY MARKET SHARE, BY END USER, 2020 (%) 50
FIGURE 11 GLOBAL EPILEPSY MARKET, BY END USER, 2020 & 2027 51
FIGURE 12 GLOBAL EPILEPSY MARKET, BY REGION, 2020 & 2027 (USD MILLION) 56
FIGURE 13 GLOBAL EPILEPSY MARKET SHARE, BY REGION, 2020 (%) 58
FIGURE 14 AMERICAS: EPILEPSY MARKET SHARE, BY REGION, 2020 (%) 59
FIGURE 15 NORTH AMERICA: EPILEPSY MARKET SHARE, BY COUNTRY, 2020 (%) 64
FIGURE 16 LATIN AMERICA: EPILEPSY MARKET SHARE, BY COUNTRY, 2020 (%) 75
FIGURE 17 EUROPE: EPILEPSY MARKET SHARE, BY REGION, 2020 (%) 87
FIGURE 18 WESTERN EUROPE: EPILEPSY MARKET SHARE, BY COUNTRY, 2020 (%) 92
FIGURE 19 ASIA-PACIFIC: EPILEPSY MARKET SHARE, BY COUNTRY, 2020 (%) 121
FIGURE 20 MIDDLE EAST AND AFRICA: EPILEPSY MARKET SHARE, BY REGION, 2020 (%) 148
FIGURE 21 MIDDLE EAST: EPILEPSY MARKET SHARE, BY COUNTRY, 2020 (%) 153
FIGURE 22 GLOBAL EPILEPSY MARKET, MARKET SHARE ANALYSIS 2020 (%) 169
FIGURE 23 GLOBAL EPILEPSY MARKET COMPETITIVE LANDSCAPE 2020 (%) 170
てんかんマーケット
てんかん市場は2023年までに950億米ドルの評価額を獲得する予定であり、2020年から2027年の評価期間にわたって8.20％のCAGRを示しています
$ 9.50 Billion
市場規模
8.20%
CAGR
North America
支配的な地域
2020-2027
予測期間
セグメンテーション
キープレーヤー
- LivaNova PLC (U.K.)
- GlaxoSmithKline PLC (U.K.)
- Eisai Co. Ltd. (Japan)
- Pfizer Inc. (U.S.)
- Medtronic PLC (Ireland)
- UCB SA (Belgium)
- NeuroPace Inc. (U.S.)
- GW Pharmaceuticals PLC (U.K.)
- Novartis AG (Switzerland)
- Johnson & Johnson Services Inc. (U.S.)
運転手
- Increasing Incidence of PTE
- The high sensitivity risk of elderly epilepsy is expected to fuel consumer demand
てんかん市場の概要
MRFRによると、てんかん市場は2023年までに950億米ドルの評価額を獲得する予定であり、評価期間（2018-2023）にわたってCAGRは8.20％です。高齢者コミュニティにおけるてんかん有病率の増加と事故誘発性脳損傷症例の増加は、市場の成長を促進する主要な要因です。
新型コロナウイルス分析
新型コロナウイルスは比較的短期間で世界中に広がり、パンデミックになりました。罹患した患者の多くは、乾いた咳、疲労感、呼吸困難、発熱などの症状を示します。しかし、Covid-19の感染は、腎臓、肝臓、神経系を含む複数の組織を破壊します。Covid-19感染の一般的な神経学的症状には、せん妄、うつ病、発熱、嗅覚と味覚の喪失が含まれます。まれに脳卒中やてんかんを引き起こす可能性があります。これにより、効率的なてんかん治療と投薬に対する需要が高まっています。さらに、COVID 19治療に向けた研究開発投資の増加も、てんかん市場の成長に貢献する可能性があります。
マーケットダイナミクス
市場の成長を促進するPTEの発生率の増加
高齢者のてんかんの高感度リスクは、消費者の需要を刺激すると予想されます。さらに、心的外傷後てんかん（PTE）および心的外傷後発作（PTS）を引き起こす可能性のある脳損傷は、てんかん業界の需要を促進する可能性があります。てんかんに対する世界的な需要は、実験薬の開発、先進地域への新薬の到着、髄膜炎や腫瘍などの神経障害の有病率などの主要な要因によっててんかん市場にも影響されています。この上昇は、医療費の改善と可処分所得の増加によってさらに促進されています。
市場機会
早期診断のための高度なイメージング技術の採用の拡大が市場の成長に貢献
難治性てんかんの革新的な治療法の設計に焦点を当てた企業や、より効果的な医薬品を必要とする医師などの新たなトレンドは、てんかん市場への研究開発投資を増やしています。合理的ポリセラピーと早期診断のための高度な画像技術の採用も市場の成長に貢献しています。さらに、mHealthや遠隔医療などの高度なデジタルヘルスケアモデルの採用は、てんかん市場の成長機会を生み出す可能性があります。
市場制約
医薬品費の上昇は市場の成長を妨げる可能性が高い
一方、需要の拡大は、時間のかかる処方承認プロセスと薬費の上昇によって妨げられています。さらに、てんかんの課題に対する認識が低いことも、てんかん市場の成長を妨げる可能性があります。実際、消費者はますますゲーム会社やソーシャルメディアプラットフォームにてんかん警告を含めるよう請願しています。
セグメントの概要
この研究レポートは、てんかんの世界市場を障害、診断とケア、および最終用途別に分類しています。
[条件別]
状態によって、てんかん市場はてんかん薬剤耐性/難治性てんかんなどに分かれています。薬剤耐性てんかんセグメントは、予測期間の終わりまでに29億3,000万米ドルの価値に達すると予想されています。副作用を最小限に抑えて疾患を治療するための合理的なポリセラピーの出現は、てんかん市場にかなりの収益をもたらすと予想されます。
診断と治療によって
診断と治療によって、てんかんのてんかん市場は診断と治療に分けられます。この治療カテゴリーは、部分てんかん発作を治療するための安価な薬剤が入手可能であるため、予測期間中にてんかん市場を7.91パーセントのCAGRで牽引すると予想される。さらに、規制当局による成功した医薬品の承認は、このセグメントの発展を促進するでしょう。一方、診断セグメントは、評価期間にわたって8.76パーセントのCAGRで成熟すると予想されます。多数の画像検査と血液検査を使用して状態の早期診断を行うと、セグメントの開発が10倍に加速すると予想されます。
最終用途別
エンドユーザーに基づいて、てんかん市場は病院、診療所、診断センター、外来手術センターなどに分割されています。病院セグメントは、レビュー期間にわたって市場の成長を支配すると宣伝され、続いてクリニックセグメントが続きます。Moさらに, 病院の敷地からの医薬品の調達を奨励する病院は、市場を促進する可能性が高い.
地域分析
この地域のてんかん産業は、南北アメリカ、ヨーロッパ、アジア太平洋（APAC）、中東およびアフリカ（MEA）に分割されています。
北米は優れた医療インフラで市場を支配しています
その中で、南北アメリカは2017年のシェアの41％を占め、ヨーロッパ、APAC、MEAが中心となった。北米は、確立されたヘルスケア施設の利用可能性、ヘルスケアセクターの強化を目的とした有益な政府政策、および実質的な研究開発プログラムの存在により、市場への主要な貢献者です。
増加する研究開発投資がヨーロッパ市場を牽引
ヨーロッパのCAGRは、予測期間にわたって 8.31% になると予想されています。てんかんの治療に成功する医薬品の研究と生産への投資の増加は、この疾患の高い有病率と相まって、地域の需要を飛躍的に促進すると予想されます。
アジア太平洋地域の市場規模を拡大する新規医薬品の開発
APACてんかん市場は、国内で報告されている状態の発生率が高いため、2023年までに204万米ドルの価値に達する予定です。また、新製品の研究と生産のための実行可能な目的地として浮上しているインド、韓国、中国の国々は、予測期間にわたって消費者の需要を刺激するでしょう。
競争環境
有力企業が採用する主要な戦術となる効率的な医薬品の生産と製品承認の増加
てんかん治療業界で活動する企業は、政府機関による承認、パートナーシップ、世界中の各地域および地域の他のてんかん市場のリーダーとの戦略的合併および買収を通じて、グローバルなリーチを強化することを計画しています。てんかん治療の世界市場における地位を強化するために、堅固な進歩的な研究開発努力と製品パイプライン、および製品承認の拡大は、これらのプレーヤーが従う重要な戦略です。市場シェアを拡大するために、主要企業のほとんどは製品ポートフォリオの強化に取り組んでいます。新薬の発売は、抗てんかん薬の市場拡大を促進すると予測されています。
2020年12月：欧州のCNSスペシャリストがMedinutrix Ltdを買収し、アイルランドで最近買収した市場をリードするてんかん治療「Buccolam」の即時プラットフォームを提供しました。
キープレイヤー
- LivanOva PLC (英国)
- グラクソ・スミスクライン PLC (英国)
- エーザイ株式会社 (日本)
- ファイザー社 (米国)
- メドトロニック PLC (アイルランド)
- UCB SA (ベルギー)
- NeuroPace Inc. (米国)
- GW ファーマシューティカルズ PLC (英国)
- ノバルティスAG (スイス)
- ジョンソン・エンド・ジョンソン・サービス株式会社（米国）
- アボット研究所 (米国)
最近の動向
2020年12月：新しいてんかん薬であるCenobamate（Xcopri）の試験で陽性の結果が示され、オープンラベル試験で発作の発生率が大幅に低下し、セノバメートを摂取した成人患者240人のうち、発作自由率は大幅に増加しました。患者による併用抗けいれん薬（ASM）の使用も制限されており、有効性にはほとんど影響しませんでした。
2020年12月：アラバマ大学バーミンガム校（UAB）により、LITTまたはレーザー間質性温熱療法と呼ばれる新しい低侵襲性てんかんレーザー手術が提案されました。特定の形態のてんかんでは、発作の原因となっている脳組織を破壊するためにレーザーを使用する新しい技術です。
レポート概要
このレポートは、世界のてんかん治療市場の成長に焦点を当てており、市場のさまざまなセグメントに関する詳細を含む市場のスナップショットを含む広範なエグゼクティブサマリーで構成されています。また、主要な参加者による地理的および市場シェア分析の観点からの市場競争力の概要を提供し、てんかん治療市場で出現している全体的な競争状況の詳細な分析を提供します。この調査はまた、その商品の世界市場に関する知識とデータ分析を提供します。
Report Scope:
| Report Attribute/Metric | Details |
|---|---|
| Market Size | USD 9.50 Billion |
| CAGR | 8.20% (2018-2023) |
| Base Year | 2019 |
| Forecast Period | 2020-2027 |
| Historical Data | 2018 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Condition, Diagnosis & Treatment and End-use |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | LivaNova PLC (U.K.), GlaxoSmithKline PLC (U.K.), Eisai Co. Ltd. (Japan), Pfizer Inc. (U.S.), Medtronic PLC (Ireland), UCB SA (Belgium), NeuroPace Inc. (U.S.), GW Pharmaceuticals PLC (U.K.), Novartis AG (Switzerland), Johnson & Johnson Services Inc. (U.S.), Abbott Laboratories (U.S.) |
| Key Market Opportunities | Growing Adoption Of Advanced Imaging Technology For Early Diagnosis |
| Key Market Drivers | Increasing Incidence of PTE to Drive Market Growth |
Frequently Asked Questions (FAQ) :
Epilepsy market is projected to grow at an 8.20% CAGR between 2020-2027.
The Americas is expected to dominate the epilepsy market.
Epilepsy market is predicted to touch USD 9,509.2 million by 2023.
Rising cases of brain injuries and prevalence of epilepsy among the older generation are the key factors driving the epilepsy market.
Hospitals will dominate the epilepsy market.
